会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • COMPOUNDS WITH PGD2 ANTAGONIST ACTIVITY
    • 具有PGD2拮抗剂活性的化合物
    • WO2005040112A1
    • 2005-05-06
    • PCT/GB2004/004337
    • 2004-10-13
    • OXAGEN LIMITEDMIDDLEMISS, DavidASHTON, Mark, RichardBOYD, Edward, AndrewBROOKFIELD, Frederick, ArthurARMER, Richard, Edward
    • MIDDLEMISS, DavidASHTON, Mark, RichardBOYD, Edward, AndrewBROOKFIELD, Frederick, ArthurARMER, Richard, Edward
    • C07D209/18
    • C07D403/12C07D209/18
    • Compounds of general formula (I); wherein R 1 , R 2 , R 3 and R 4 are independently hydrogen, halo, -C 1 -C 6 alkyl, -O(C 1 -C 6 alkyl), -C 1 -C 6 alkyl(C 3 -C 7 cycloalkyl), -CON(R 9 ) 2 , -SOR 9 , -S0 2 R 9 . -S0 2 N(R 9 ) 2 , -N(R 9 ) 2 , -NR 9 OR 9 , -C0 2 R 9 , COR 9 , -SR 9 , -OH, -N0 2 or -CN; each R 9 independently hydrogen or C 1 -C 6 alkyl; R 5 and R 6 are each independently hydrogen, or C 1 -C 6 alkyl or together with the carbon atom to which they are attached form a C 3 -C 7 cycloalkyl. group; R 7 is hydrogen or C 1 -C 6 alkyl; R 8 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or an aromatic moiety, any of which may optionally be substituted with one or more substituents selected from halo, -SOR 13 -S0 2 R 13 , -R 14 , -OR 14 , -CON(R 14 )2 -SOR 14 , -S0 2 R 14 , -S0 2 N(R 14 ) -SO 2 N(R 14 ) 2 , -N(R 14 )2, NR 14 COR 14 , -CO 2 R 14 , COR 14 , -SR 14 , -N0 2 or -CN; wherein R 13 is a 5 to 7 membered heterocyclic ring; and each R 14 is independently hydrogen, alkyl or aryl, the aryl being optionally substituted by -R 9 , -OR 9 , -CON(R 9 ) 2 , -SOR 9 -S0 2 R 9 , -S0 2 N(R 9 ) 2 , -N(R 9 ) 2 , NR9COR 9 , -C0 2 R 9 , -COR 9 , -SR 9 , halo, -N0 2 or -CN; wherein R 9 is as defined above; provided that when R 1 , R 3 and R 4 are hydrogen and R 2 is hydrogen, halogen or -O(C 1 -C 6 )alkyl, R 8 is not unsubstituted phenyl or phenyl substituted by halo, C 1 -C 6 alkyl, -O(C 1 -C 6 )alkyl, -S(C 1 -C 6 )alkyl or -CO(C 1 -C 6 )alkyl; or pharmaceutically acceptable salts, hydrates, solvates, compexes or prodrugs therof are useful in the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.
    • 通式(I)的化合物; 其中R 1,R 2,R 3和R 4独立地是氢,卤素,-C 1 -C 6烷基,-O(C 1 -C 6烷基),-C 1 -C 6烷基(C 3 -C 7 环烷基),-CON(R 9)2,-SOR 9,-SO 2 R 9。 -SO 2 N(R 9)2,-N(R 9)2,-NR 9 OR 9,-CO 2 R 9,COR 9,-SR 9,-OH, -NO 2或-CN; 每个R 9独立地是氢或C 1 -C 6烷基; R 5和R 6各自独立地为氢或C 1 -C 6烷基,或与它们所连接的碳原子一起形成C 3 -C 7环烷基。 组; R 7是氢或C 1 -C 6烷基; R 8是C 1 -C 6烷基,C 2 -C 6烯基,C 2 -C 6炔基或芳族部分,其中任何一个可任选地被一个或多个选自卤素,-SOR 13 -SO 2 R 13, ,-R 14,-OR 14,-CON(R 14)2 -SOR 14,-SO 2 R 14,-SO 2 N(R 14)-SO 2 N(R 14)2,-N(R COR 14,-C 14 R 14,COR 14,-SR 14,-NO 2或-CN; 其中R 13为5至7元杂环; 并且每个R 14独立地为氢,烷基或芳基,芳基任选被-R 9,-OR 9,-CON(R 9)2,-SOR 9 - (R 9)2,-N(R 9)2,NR 9 COR 9,-CO 2 R 9,-COR 9,-SR 9,卤素,-NO 2 或-CN; 其中R 9如上所定义; 条件是当R 1,R 3和R 4为氢且R 2为氢,卤素或-O(C 1 -C 6)烷基时,R 8为未取代的苯基或被 卤素,C 1 -C 6烷基,-O(C 1 -C 6)烷基,-S(C 1 -C 6)烷基或-CO(C 1 -C 6)烷基; 或其药学上可接受的盐,水合物,溶剂合物,混合物或前药可用于治疗过敏性疾病如哮喘,过敏性鼻炎和特应性皮炎。